CRISPR-suppressor Scanning Reveals a Nonenzymatic Role of LSD1 in AML

Overview

Journal Nat Chem Biol

Specialties Biochemistry
Biology
Chemistry

Date 2019 Apr 18

PMID 30992567

Citations 54

Authors

Michael E Vinyard

Cindy Su

Allison P Siegenfeld

Amanda L Waterbury

Allyson M Freedy

Pallavi M Gosavi

Yongho Park

Eugene E Kwan

Benjamin D Senzer

John G Doench

Daniel E Bauer

Luca Pinello

Brian B Liau

Affiliations

Soon will be listed here.

Abstract

Understanding the mechanism of small molecules is a critical challenge in chemical biology and drug discovery. Medicinal chemistry is essential for elucidating drug mechanism, enabling variation of small molecule structure to gain structure-activity relationships (SARs). However, the development of complementary approaches that systematically vary target protein structure could provide equally informative SARs for investigating drug mechanism and protein function. Here we explore the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML). Through this approach, termed CRISPR-suppressor scanning, we elucidate drug mechanism of action by showing that LSD1 enzyme activity is not required for AML survival and that LSD1 inhibitors instead function by disrupting interactions between LSD1 and the transcription factor GFI1B on chromatin. Our studies clarify how LSD1 inhibitors mechanistically operate in AML and demonstrate how CRISPR-suppressor scanning can uncover novel aspects of target biology.

Citing Articles

Converging mechanism of UM171 and KBTBD4 neomorphic cancer mutations.

Xie X, Zhang O, Yeo M, Lee C, Tao R, Harry S Nature. 2025; 639(8053):241-249.

PMID: 39939763 PMC: 11882451. DOI: 10.1038/s41586-024-08533-3.

UM171 glues asymmetric CRL3-HDAC1/2 assembly to degrade CoREST corepressors.

Yeo M, Zhang O, Xie X, Nam E, Payne N, Gosavi P Nature. 2025; 639(8053):232-240.

PMID: 39939761 PMC: 11882444. DOI: 10.1038/s41586-024-08532-4.

Copy number amplification of FLAD1 promotes the progression of triple-negative breast cancer through lipid metabolism.

Song X, Yu T, Ou-Yang Y, Ding J, Jiang Y, Shao Z Nat Commun. 2025; 16(1):1241.

PMID: 39890808 PMC: 11785949. DOI: 10.1038/s41467-025-56458-w.

Uncoupling histone modification crosstalk by engineering lysine demethylase LSD1.

Lee K, Barone M, Waterbury A, Jiang H, Nam E, DuBois-Coyne S Nat Chem Biol. 2024; 21(2):227-237.

PMID: 38965385 PMC: 11699879. DOI: 10.1038/s41589-024-01671-9.

An autoinhibitory switch of the LSD1 disordered region controls enhancer silencing.

Waterbury A, Kwok H, Lee C, Narducci D, Freedy A, Su C Mol Cell. 2024; 84(12):2238-2254.e11.

PMID: 38870936 PMC: 11193646. DOI: 10.1016/j.molcel.2024.05.017.

References

Dawson M, Kouzarides T . Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150(1):12-27. DOI: 10.1016/j.cell.2012.06.013. View

Maiques-Diaz A, Spencer G, Lynch J, Ciceri F, Williams E, Amaral F . Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia. Cell Rep. 2018; 22(13):3641-3659. PMC: 5896174. DOI: 10.1016/j.celrep.2018.03.012. View

Saleque S, Kim J, Rooke H, Orkin S . Epigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1. Mol Cell. 2007; 27(4):562-72. DOI: 10.1016/j.molcel.2007.06.039. View

Shen L, Shao N, Liu X, Nestler E . ngs.plot: Quick mining and visualization of next-generation sequencing data by integrating genomic databases. BMC Genomics. 2014; 15:284. PMC: 4028082. DOI: 10.1186/1471-2164-15-284. View

Dawson M . The cancer epigenome: Concepts, challenges, and therapeutic opportunities. Science. 2017; 355(6330):1147-1152. DOI: 10.1126/science.aam7304. View

Heinz S, Benner C, Spann N, Bertolino E, Lin Y, Laslo P . Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010; 38(4):576-89. PMC: 2898526. DOI: 10.1016/j.molcel.2010.05.004. View

Cai S, Chen C, Armstrong S . Drugging Chromatin in Cancer: Recent Advances and Novel Approaches. Mol Cell. 2015; 60(4):561-70. PMC: 4701197. DOI: 10.1016/j.molcel.2015.10.042. View

Ishikawa Y, Gamo K, Yabuki M, Takagi S, Toyoshima K, Nakayama K . A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells. Mol Cancer Ther. 2016; 16(2):273-284. DOI: 10.1158/1535-7163.MCT-16-0471. View

Niwa H, Sato S, Hashimoto T, Matsuno K, Umehara T . Crystal Structure of LSD1 in Complex with 4-[5-(Piperidin-4-ylmethoxy)-2-(-tolyl)pyridin-3-yl]benzonitrile. Molecules. 2018; 23(7). PMC: 6099836. DOI: 10.3390/molecules23071538. View

10.

Baron R, Binda C, Tortorici M, McCammon J, Mattevi A . Molecular mimicry and ligand recognition in binding and catalysis by the histone demethylase LSD1-CoREST complex. Structure. 2011; 19(2):212-20. PMC: 3059804. DOI: 10.1016/j.str.2011.01.001. View

11.

Pattanayak V, Lin S, Guilinger J, Ma E, Doudna J, Liu D . High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol. 2013; 31(9):839-43. PMC: 3782611. DOI: 10.1038/nbt.2673. View

12.

Lin Y, Wu Y, Li J, Dong C, Ye X, Chi Y . The SNAG domain of Snail1 functions as a molecular hook for recruiting lysine-specific demethylase 1. EMBO J. 2010; 29(11):1803-16. PMC: 2885925. DOI: 10.1038/emboj.2010.63. View

13.

Forneris F, Orru R, Bonivento D, Chiarelli L, Mattevi A . ThermoFAD, a Thermofluor-adapted flavin ad hoc detection system for protein folding and ligand binding. FEBS J. 2009; 276(10):2833-40. DOI: 10.1111/j.1742-4658.2009.07006.x. View

14.

Lee M, Wynder C, Schmidt D, McCafferty D, Shiekhattar R . Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem Biol. 2006; 13(6):563-7. DOI: 10.1016/j.chembiol.2006.05.004. View

15.

Cusan M, Cai S, Mohammad H, Krivtsov A, Chramiec A, Loizou E . LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML. Blood. 2018; 131(15):1730-1742. PMC: 5897868. DOI: 10.1182/blood-2017-09-807024. View

16.

Takagi S, Ishikawa Y, Mizutani A, Iwasaki S, Matsumoto S, Kamada Y . LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B. Cancer Res. 2017; 77(17):4652-4662. DOI: 10.1158/0008-5472.CAN-16-3502. View

17.

Burg J, Gonzalez J, Maksimchuk K, McCafferty D . Lysine-Specific Demethylase 1A (KDM1A/LSD1): Product Recognition and Kinetic Analysis of Full-Length Histones. Biochemistry. 2015; 55(11):1652-62. PMC: 4803528. DOI: 10.1021/acs.biochem.5b01135. View

18.

Shi Y, Lan F, Matson C, Mulligan P, Whetstine J, Cole P . Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004; 119(7):941-53. DOI: 10.1016/j.cell.2004.12.012. View

19.

Harris W, Huang X, Lynch J, Spencer G, Hitchin J, Li Y . The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell. 2012; 21(4):473-87. DOI: 10.1016/j.ccr.2012.03.014. View

20.

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View